35,652 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Neo Ivy Capital Management

Neo Ivy Capital Management purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 35,652 shares of the biopharmaceutical company's stock, valued at approximately $744,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CPRX. Vanguard Group Inc. increased its holdings in Catalyst Pharmaceuticals by 4.9% during the 4th quarter. Vanguard Group Inc. now owns 8,431,094 shares of the biopharmaceutical company's stock worth $175,957,000 after purchasing an additional 390,116 shares during the last quarter. Pacer Advisors Inc. increased its stake in shares of Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company's stock worth $61,681,000 after buying an additional 151,495 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Catalyst Pharmaceuticals by 7.1% in the fourth quarter. Renaissance Technologies LLC now owns 2,706,116 shares of the biopharmaceutical company's stock valued at $56,477,000 after acquiring an additional 180,100 shares in the last quarter. Castlekeep Investment Advisors LLC acquired a new stake in Catalyst Pharmaceuticals in the fourth quarter valued at $37,494,000. Finally, Bank of America Corp DE boosted its stake in Catalyst Pharmaceuticals by 139.5% during the 4th quarter. Bank of America Corp DE now owns 1,568,791 shares of the biopharmaceutical company's stock valued at $32,741,000 after acquiring an additional 913,843 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company's stock.

Insider Buying and Selling

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the transaction, the insider now owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Gary Ingenito sold 200,000 shares of the business's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the sale, the insider now owns 68,873 shares in the company, valued at $1,630,912.64. This trade represents a 74.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 351,879 shares of company stock valued at $8,214,815 in the last quarter. Company insiders own 10.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Robert W. Baird boosted their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Wall Street Zen upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. Finally, Stephens reiterated an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Seven equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of "Buy" and an average price target of $32.29.

Catalyst Pharmaceuticals Stock Down 1.2%

NASDAQ CPRX traded down $0.30 during trading hours on Wednesday, hitting $24.54. The company had a trading volume of 684,682 shares, compared to its average volume of 1,103,813. The firm has a market cap of $2.99 billion, a P/E ratio of 20.80, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.75 and a fifty-two week high of $26.16. The business has a fifty day simple moving average of $23.61 and a 200-day simple moving average of $22.57.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.